The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy?

REFERENCES

• Winer E. P., Hudis C., Burstein H. J., Wolff A. C., Pritchard K. I. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin Oncol. 2005; 23: 619–629
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Glick J. H., Gelber R. D., Coates A. S., Thurlimann B., Senn H. J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16: 1569–1583
   PubMed Web of Science ®Google Scholar
• Thurlimann B., Keshaviah A., Coates A. S., Mouridsen H., Mauriac L. Breast International Group (BIG) 1–98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005; 353: 2747–2757
   PubMed Web of Science ®Google Scholar
• Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62
   PubMed Web of Science ®Google Scholar
• Rose C., Vtoraya O., Pluzanska A., Davidson N., Gershanovich M. An open randomized trial of second-line endocrine therapy in advanced breast cancer, comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 2003; 39: 2318–2327
   PubMed Web of Science ®Google Scholar
• Geisler J., Haynes B., Anker G., Dowsett M., Lonning P. E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross over study. J. Clin. Oncol. 2002; 20: 751–757
   PubMed Web of Science ®Google Scholar
• Dixon J. M., Renshaw L., Young O., Murray J., Macaskill D. J. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. Proc. Am. Soc. Clin. Oncol. 2006; 24: 15S, Abstr. 552
   Web of Science ®Google Scholar
• Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 2005; 23: 7512–7517
   PubMed Web of Science ®Google Scholar
• Viale G., Regan M., Dell'Orto P., Del Curto B., Braye S. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res. Treat. 2005; 94: 44a, Suppl.1
   Google Scholar
• Buzdar, A. U. On behalf of the ATAC Trialists' group. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the Arimidex. Tamoxifen. Alone or in Combination (ATAC) trial. J. Clin. Oncol. 2005; 23: 30s, (Suppl.16) (Abstr. 608)
   PubMed Web of Science ®Google Scholar
• Goss P. E., Ingle J. N., Martino S., Robert N. J., Muss H. B. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J. Natl. Cancer Inst. 2005; 97: 1262–1271
   PubMed Web of Science ®Google Scholar
• Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Eur. J. Cancer Suppl. 2006; 4(2)111, Abstr. 219
   Google Scholar
• McArthur H. L., Olivotto I., Gelmon K. A., Speers C. H., Chia S., Ellard S., Kennecke H. F. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res. Treat. 2005; 94: S124, (Suppl. 1) (Abstr. 3001)
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Mouridsen H., Robert N. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur. J. Cancer 2005; 41: 1678–1689
   PubMed Web of Science ®Google Scholar
• De Boer R., Burris H., Monnier A., Mouridsen H., O'Shaughnessy J. On behalf of the H211 trial steering committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc. Soc. Clin. Oncol. 2006; 24: 582S, Abstr. 10672
   Google Scholar